Pacira Pharmaceuticals Inc. (PCRX) Tops Q2 EPS by 7c; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Join SI Premium – FREE
Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) reported Q2 EPS of ($0.51), $0.07 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $3.5 million.
Reaffirms outlook.
Reaffirms outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
